71719-06-7

Basic information

• Product Name: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE
• Synonyms: 5-BROMO-3-(2-PYRROLIDINYL)PYRIDINE;3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE;3-BROMO-5-PYRROLIDIN-2-YL-PYRIDINE;(S)-3-bromo-5-(pyrrolidin-2-yl)pyridine hydrochloride;(R,S)-3-BroMo Nornicotine
• CAS NO: 71719-06-7
• Molecular Formula: C₉H₁₁BrN₂
• Molecular Weight: 227.1
• EINECS: 200-258-5
• Product Categories: Heterocycles;Nicotine Derivatives;Aromatics;Chiral Reagents;Mutagenesis Research Chemicals
• Mol File: 71719-06-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 295.4°C at 760 mmHg
• Flash Point: 132.5°C
• Appearance: /
• Density: 1.434g/cm³
• Vapor Pressure: 0.00153mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.56±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE(71719-06-7)
• EPA Substance Registry System: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE(71719-06-7)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 71719-06-7(Hazardous Substances Data)

Usage

Uses

3-Bromo-5-(2-pyrrolidinyl)pyridine is a Nornicotine (N757000) analog used as haptens for immunoassays.

InChI:InChI=1/C9H11BrN2/c10-8-4-7(5-11-6-8)9-2-1-3-12-9/h4-6,9,12H,1-3H2

Upstream product

• 201610-91-5 5-bromo-3-(2-pyrrolin-1-yl)pyridine 
• 201292-62-8 3-(5-Bromo-pyridine-3-carbonyl)-1-vinyl-pyrrolidin-2-one 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 64319-85-3 3-bromo-5-(4,5-dihydro-3H-pyrrol-2-yl)-pyridine 

Downstream Products

• 71719-09-0 5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine 
• 7076-23-5 (+)-nornicotine 

Relevant articles and documents

Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo

Since the demonstration of nicotine vaccines as a possible therapeutic intervention for the effects of tobacco smoke, extensive effort has been made to enhance nicotine specific immunity. Linker modifications of nicotine haptens have been a focal point for improving the immunogenicity of nicotine, in which the evaluation of these modifications usually relies on in vivo animal models, such as mice, rats or nonhuman primates. Here, we present two in vitro screening strategies to estimate and predict the immunogenic potential of our newly designed nicotine haptens. One utilizes a competition enzyme-linked immunoabsorbent assay (ELISA) to profile the interactions of nicotine haptens or hapten-protein conjugates with nicotine specific antibodies, both polyclonal and monoclonal. Another relies on computational modeling of the interactions between haptens and amino acid residues near the conjugation site of the carrier protein to infer linker-carrier protein conjugation effect on antinicotine antibody response. Using these two in vitro methods, we ranked the haptens with different linkers for their potential as viable vaccine candidates. The ELISA-based hapten ranking was in an agreement with the results obtained by in vivo nicotine pharmacokinetic analysis. A correlation was found between the average binding affinity (IC50) of the haptens to an anti-Nic monoclonal antibody and the average brain nicotine concentration in the immunized mice. The computational modeling of hapten and carrier protein interactions helps exclude conjugates with strong linker-carrier conjugation effects and low in vivo efficacy. The simplicity of these in vitro screening strategies should facilitate the selection and development of more effective nicotine conjugate vaccines. In addition, these data highlight a previously under-appreciated contribution of linkers and hapten-protein conjugations to conjugate vaccine immunogenicity by virtue of their inclusion in the epitope that binds and activates B cells.

COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES

The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolidine derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils.

MODULATORS OF ACETYLCHOLINE RECEPTORS

The present invention provides a class of pyridine compounds which are modulators of acetylcholine receptors, i.e., compounds which displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists